|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.72 USD | 0.00% |
|
-2.82% | -4.91% |
| Feb. 27 | UBS Adjusts Price Target on Harmony Biosciences to $55 From $56, Keeps Buy Rating | MT |
| Feb. 25 | Harmony Biosciences Holdings, Inc., Q4 2024 Earnings Call, Feb 25, 2025 |
Summary: Harmony Biosciences Holdings, Inc.
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to MSCI, which ranks companies by sector.
Highlights: Harmony Biosciences Holdings, Inc.
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- With a P/E ratio at 10.98 for the current year and 8.24 for next year, earnings multiples are highly attractive compared with competitors.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: Harmony Biosciences Holdings, Inc.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings Chart: Harmony Biosciences Holdings, Inc.
Source: Surperformance
ESG chart: Harmony Biosciences Holdings, Inc.
Source: MSCI
| Fundamentals | Valuation | Revisions of Fundamental Estimates | Capi.($) | ||
|---|---|---|---|---|---|
| 1.88B | |||||
| 731B | |||||
| 392B | |||||
| 374B | |||||
| 343B | |||||
| 277B | |||||
| 240B | |||||
| 239B | |||||
| 215B | |||||
| 169B | |||||
| Average | 298.13B | ||||
| Weighted average by Cap. |
Investor
Trader
ESG MSCI
BB
Financials
Sales growth
EPS Growth
Profitability
Net margin
Financial Health
Valuation
P/E ratio
EV/REVENUE
EV/EBITDA
PBR
Yield
-
Revisions
1 year Revenue revision
4 months Revenue revision
1 months Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analysts' recommendations
4m Revision of opinion
Potential Price Target
4m Target Price Revision
12m Target Price Revision
Business Predictability
Earnings quality
Analyst Coverag
Divergence of analysts' recommendations
Divergence of Target Price
Divergence of analysts' opinions
ESG
ESG: Environment
ESG: Social
ESG: Governance
ESG: Controversy
ESG: Ethical controversies
ESG: Human rights controversies
ESG: Tax subsidies controversies
ESG: Sharia compliant
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- HRMY Stock
- Ratings Harmony Biosciences Holdings, Inc.